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Abstract
Neuroendocrine neoplasms of the large intestine account for 20% of all neuroendocrine neoplasms (NENs) and are most commonly 
found in the rectum. The rate of detection of colorectal NENs is increasing, and this tendency will continue due to the widespread use of 
colonoscopy as a screening tool and the removal of all diagnosed lesions. 
This paper provides updated guidelines for the management of patients with colorectal NENs. Recent data on epidemiology, clinical 
characteristics, biochemical, and pathomorphological diagnosis as well as useful imaging techniques are presented. We look in detail at 
novel methods of treatment including endoscopic and surgical management, pharmacological and radioisotope therapy. We summarise 
monitoring of the treatment. (Endokrynol Pol 2013; 64 (6): 494–504)
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Streszczenie
Nowotwory neuroendokrynne (NENs) jelita grubego stanowią 20% wszystkich nowotworów neuroendokrynnych. Najczęstszą ich 
lokalizacją jest odbytnica. Nowotwory neuroendokrynne jelita grubego są wykrywane coraz częściej i liczba ta będzie wzrastać z uwagi 
na powszechność wykonywania kolonoskopii, w tym badań przesiewowych oraz usuwanie wykrytych zmian. W pracy przedstawiono 
aktualne zalecenia dotyczące diagnostyki i terapii NEN jelita grubego, z uwzględnieniem diagnostyki biochemicznej, patomorfologicznej, 
nowych technik obrazowania oraz leczenia endoskopowego, chirurgicznego, farmakologicznego i radioizotopowego. Omówiono także 
epidemiologię, charakterystykę kliniczną i monitorowanie leczenia. (Endokrynol Pol 2013; 64 (6): 494–504)
Słowa kluczowe: nowotwory neuroendokrynne jelita grubego; epidemiologia; diagnostyka; leczenie; monitorowanie 
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1. Epidemiology
1.1. Introduction 
The rate of detection of colorectal neuroendocrine 
neoplasms (NENs) is increasing, and this tendency will 
continue due to the widespread use of colonoscopy as 
a screening tool and the removal of all diagnosed lesions 
[1–5, 9, 12]. As the prognosis and management methods 
in colorectal NENs located in the colon differ from those 
for rectal NENs, they are discussed separately. 
1.2. Epidemiology
Colonic NENs account for 7.8%, and rectal NENs for 
13.7%, of all neuroendocrine neoplasms [2]. The most 
common site for colonic tumours is the caecum, and this 
location of the disease is more frequent in females [2]. 
The average age at disease onset is 70 years [3]. Rectal 
tumours are the third largest group of gastrointestinal 
NENs. They account for approximately 1% of all rectal 
tumours [6]. They are detected by one in 1,000-2,000 
endoscopic examinations [1, 5, 7–9].
According to Japanese authors, rectal NENs are 
slightly more common in the male population (M/F 
ratio — 1.5) [10], whereas American and Polish data 
demonstrates a similar prevalence of these neoplasms 
in both sexes [2, 5, 9]. The mean age of patients is 56 
years. Current statistical data indicates 4.2 cases of rectal 
NENs in every 1,000,000 citizens [11].
2. Clinical characteristics
2.1. Clinical characteristics and symptomatology
Colorectal neuroendocrine neoplasms arise from two 
types of cells:
 — EC (enterochromaffin) cells, which secrete seroto-
nin, are mostly located in the ascending colon; 
 — L cells, which secrete glucagon-like peptide (GLP) 
and YY peptide, are found in the remaining part of 
the colon and rectum.
Colorectal NENs characteristically do not secrete 
specific hormones, and their clinical symptoms correlate 
with the location and stage of advancement. 
The symptoms associated with colonic neuroendo-
crine neoplasms are non-specific. They mainly include 
changes in bowel movement (mostly diarrhoea), and 
in the case of advanced disease — abdominal pain, 
weight loss, and palpable lesions in the abdominal 
cavity. Weakness and decreased effort tolerance, often 
associated with gastrointestinal blood loss, may also oc-
cur. Moreover, patients may suffer from gastrointestinal 
obstruction, which often requires an urgent surgical 
intervention. The above symptoms are similar for all 
neoplasms occurring in this part of the gastrointestinal 
tract, suggesting the initial diagnosis of the most com-
mon neoplasm affecting this area, adenocarcinoma. 
Despite the presence of serotonin-producing cells, 
carcinoid syndrome with its characteristic symptoms 
is rarely observed (< 5%) [3]. According to the largest 
database, SEER, local lesions account for approximately 
45% at the moment of diagnosis [13]. Distant metas-
tases are found in 16–40% of patients. The five-year 
survival rate in colonic tumours, the lowest of all the 
gastrointestinal neuroendocrine neoplasms, is 40–70%, 
depending on the size of the primary tumour, histologi-
cal grade and clinical stage [2, 11, 13]. The mean survival 
is 261 months for localised lesions, but becomes much 
shorter in the case of regional lymph nodes metasta-
ses or distant metastases (36 months and five months, 
respectively) [13].
Rectal NENs are most frequently detected acciden-
tally during endoscopic examination. The symptoms 
are also non-specific, including changes in bowel move-
ment, gastrointestinal bleeding or tenesmus. Carcinoid 
syndrome almost never occurs, due to the very rare 
presence of EC serotonin-secreting cells in this loca-
tion (0.1%). At the moment of diagnosis, the majority 
(75–85%) of detected lesions are localised; distant me-
tastases are rare, accounting for 2–8% of all cases [2, 13], 
which has a significant impact on the prognosis. The 
five-year survival rate is 75–88%, depending on the 
histological grade, proliferation index and clinical stage 
[2]. The mean survival in the case of locally advanced 
tumours is 290 months, but if the regional lymph nodes 
metastases or distant metastases occur, it is 90 months 
and 22 months, respectively [13]. 
MEN syndrome and other genetically conditioned 
syndromes are very rarely associated with colorectal 
NENs [12]. NENs in first-degree family members in-
crease the risk of the disease by four times. 
In 13% of patients with a colorectal NEN, another 
neoplasm develops [2, 4, 5]. The gastrointestinal tract, 
including intestines, is the most common site for 
synchronic tumours, while metachronous neoplasms 
affect the lungs, prostate gland and urinary tract. The 
detection of gastric GIST as a metachronous tumour 
in a patient with rectal NEN and hepatic and osse-
ous metastases has recently been presented by Polish 
authors [59].
3. Diagnostics
3.1. Biochemical diagnostics
We do not have a specific marker for colorectal neu-
roendocrine neoplasms. Determination of serum 
chromogranin A (CgA) concentration is still the 
most valuable method of monitoring, therapy and 
anticipating the course of the disease. CgA concentra-
tion may be elevated and correlate with the severity 
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Table I. The pathogenesis of colorectal NENs
Tabela I. Patogeneza NEN okrężnicy i odbytnicy
Enterochromaffin 
cell (EC)
EC cell NENs are neuroendocrine neoplasms of the 
midgut (midgut-type NEN):
— they arise mainly in the right part of the colon
— they produce serotonin
— they present histological and cytochemical 
characteristics similar to NENs in the ileocaecal 
area
— morphologically, they form solid nests 
surrounded by a circumferential palisade 
of cells, sometimes rosette or cribriform 
structures, very rarely solid fields
— desmoplastic stroma is often found
— differentiation grade corresponds to G1 or G2
— tumour diameter is approximately 4.9 cm
— positive cdx2 immunoexpression
L cell L cell NENs are neoplasms of the hindgut (hindgut 
type NEN):
— they are found in the distal section of the colon 
and rectum
— they produce glucagon-like peptides, PP/PYY, 
serotonin (30%) and somatostatin (20%)
— they usually form submucosal, single polyp-like 
nodules covered by the intestinal epithelium
— over 50% of the tumours are smaller than 1 cm
— in the microscopic image they create trabecular 
structures, rarely rosette or tubular structures
— they do not demonstrate immunoexpression of 
cdx2
of the neoplastic disease, but frequently it is only 
slightly increased or remains normal [14–16, 61, 63] 
(*evidence level 3).
As tumours in this part of the gastrointestinal 
tract rarely secrete serotonin, the concentration of 
5-hydroxyindoleacetic acid in the 24-hour urine col-
lection usually remains normal. The concentration 
of serum acid phosphatase may be elevated in the 
case of neoplasms demonstrating expression of the 
prostate-specific fraction [17, 18]. The human chori-
onic gonadotropin levels may also be increased [19] 
(*evidence level 5). 
In certain cases of tumours derived from the rectum, 
it can be helpful to determine the levels of the pancre-
atic polypeptide or enteroglucagon secreted by the 
neoplastic cells, but the usefulness of this type of tests 
has not been confirmed yet (*evidence level 5). 
Minimal consensus on biochemical tests:
CgA assessment may be helpful. 
3.2. Pathomorphological diagnostics
3.2.1. Pathogenesis
Colorectal NENs are divided into colonic NENs and 
rectal NENs, depending on their anatomical location. 
Their anatomical location is related to the prognosis 
and the diagnostic algorithm. Colonic tumours are most 
frequently found in its proximal section, i.e. in the cae-
cum. Similarly to the above discussed NENs in different 
gastrointestinal locations, colorectal neuroendocrine 
neoplasms are divided into well-differentiated neuroen-
docrine neoplasms: NENs G1 and NENs G2, neuroen-
docrine carcinomas (NECs): large- or small-cell and 
mixed adenoneuroendocrine carcinomas (MANECs). 
Colonic NENs are potentially malignant neoplasms. At 
the early stage they create polyps, which macroscopi-
cally resemble adenomas. However, at the moment of 
diagnosis they are usually exophytic tumours, in the 
microscopic assessment diagnosed as neuroendocrine 
carcinomas or mixed neoplasms (MANEC). Most co-
lonic NENs are highly malignant, and at the diagnosis 
approximately 30% of cases present metastases to the 
lymph nodes, mesentery, peritoneum and liver. Rectal 
NENs are a different group; they are usually polyps 
of 1 to 2 cm in diameter, with the morphology of well-
differentiated neoplasms (NEN G1, G2), infiltrating 
the mucosa and/or submucosa. However, rectal NENs 
demonstrate an aggressive clinical course. At the mo-
ment of diagnosis, metastases to the lymph nodes are 
often found. Colorectal NECs are highly malignant neo-
plasms. Carcinomas arising from the large cells amount 
for approximately 75% of all colorectal NECs, and are 
more frequently located in the right part of the colon. 
Sometimes they are associated with adenomas and 
adenocarcinomas. Their mitotic activity is high (median 
of 34/10 HPF), and proliferative activity is more than 
20%. Immunohistochemical examination sometimes 
indicates a low CgA expression, and high expression 
of synaptophysin and CD 56. Small-cell carcinomas 
account for 25% of colorectal carcinomas, and are usu-
ally found in the distal section of the colon and rectum. 
They may be associated with squamous cell carcinoma 
or classic adenocarcinoma. They demonstrate the ex-
pression of chromogranin A and synaptophysin; some 
tumours are cdx2-positive and TTF1-positive. The Ki-67 
proliferation index is above 50%, usually close to 100% 
[62]. It should be emphasised that rectal NENs in 28 
to 82% express prostatic acid phosphatase, a potential 
diagnostic pitfall for tumours arising in male patients 
(Table I).
* evidence level according to CEBM [65]
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3.2.2. Diagnostic algorithm
In macroscopic assessment, the following elements are 
considered:
1. The length of the part of the intestine obtained for 
examination, with the description of the tumour 
location relative to the intestine resection margins 
(proximal, distal and circumferential or radial mar-
gin, examined in the segments of the large bowel 
either unencased or incompletely encased by peri-
toneum — should be marked with ink).
2. Tumour assessment: number, size in three di-
mensions, mutual relation of the tumours, cross-
section appearance, considering extravasation 
and foci of necrosis, relation of the tumour to the 
intestinal wall layers.
3. Condition of the mucosa at the tumour site (ulcera-
tion present/not present).
4. Condition of the serosa at the tumour site.
5. Presence and size of the lymph nodes.
6. Presence of other tumours in the intestinal wall.
Microscopic assessment is based on the assessment of 
the following parameters:
1. Histological type of the NEN according to the WHO 
2010 classification.
2. The histological grade G according to ENETS/WHO 
2010.
3. Pathomorphological pTNM staging according to 
ENETS and AJCC/UICC.
4. Assessment of immunohistochemical expression 
of neuroendocrine markers: chromogranin A and 
synaptophysin, as well the Ki-67/MIB1 proliferative 
activity (obligatory).
5. Immunohistochemical assessment of the markers: 
NSE, CD56, CDX2, and serotonin (conditional).
6. Assessment of surgical margins.
Regarding 1 and 2: Histopathological type of colorectal 
NENs according to the WHO 2010 classification and the 
histological grade of the NEN according to the integrated 
ENETS/WHO 2010 system are presented in "Diagnostic 
and therapeutic guidelines for gastro-entero-pancreatic 
neuroendocrine neoplasms (recommended by the Pol-
ish Network of Neuroendocrine Tumors)" (pp. 418–443).
Regarding 3: Pathological pTNM and clinical staging.
The staging of colorectal neuroendocrine neo-
plasms is verified using the TNM classification ac-
cording to AJCC/UICC and ENETS. As for this neo-
plasm location, both classifications are consistent. It is 
important, however, that the European Neuroendo-
crine Tumour Society classification is also applied to 
neuroendocrine carcinomas. According to the AJCC/ 
/UICC classification, NECs are assessed by the same 
criteria as adenocarcinomas, not as neuroendocrine 
neoplasms. Table II presents TNM classification ac-
cording to UICC/AJCC and ENETS criteria. Table III 
presents the assessment criteria for clinical staging 
of colorectal NENs.
3.3. Prognostic indicators in the histopathological 
report
The risk factors of colorectal NEN associated with me-
tastases include: tumour over 2 cm in diameter, invasion 
of the muscular layer of the colorectal wall, vasoinva-
sion, and more than two mitotic figures/10 HPF. It is rec-
ommended to determine the focal coagulative tumour 
necrosis, which indicates a more aggressive tumour. 
An important parameter in the histopathological re-
port on a colorectal NEN is the assessment of the proximal, 
distal and circumferential margin (radial or mesenteric). 
The circumferential margin is assessed in the segments of 
gastrointestinal tract either unencased or incompletely en-
cased by peritoneum. It should be noted that during mac-
roscopic assessment of the surgical material, it should be 
marked with ink. It is recommended to note the distance 
between the tumour foci with the deepest infiltrations 
and the circumferential (radial) margin line. A margin of 
Table II. TNM ENETS and UICC/AJCC classification of 
colorectal NENs 
Tabela II. Klasyfikacja TNM UICC/AJCC, ENETS NEN 
okrężnicy i odbytnicy
Feature T  
— primary tumour
Comment
pTX Primary tumour cannot be assessed
pT0 No evidence of primary tumour
pT1
pT1a
pT1b
Tumour invades mucosa and submucosa, size 
≤ 2cm
Tumour size < 1 cm in diameter
Tumour size 1–2 cm in diameter
pT2 Tumour invades muscularis propria or size > 2 
cm and invasion of mucosa or submucosa
pT3 Tumour penetrates muscularis propria and 
invades subserosa or the fat tissue of the 
sections unencased by peritoneum
Table III. Colorectal GEP NENs staging
Tabela III. Ocena stopnia klinicznego zaawansowania NEN 
jelita grubego
Stage TNM feature
Stage I T1 N0 M0
Stage IIa T2 N0 M0
Stage IIb T3 N0 M0
Stage IIIa T4 N0 M0
Stage IIIb Any T N1 M0
Stage IV Any T Any N M1
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> 1 mm indicates complete resection, whereas a margin 
of ≤ 1 mm is interpreted as incomplete.
Minimal consensus on pathology:
Minimal histopathological report on colorectal NEN 
should include:
 — histological type of the neoplasm according to WHO clas-
sification, considering the division into well-differentiated 
neuroendocrine neoplasms (NEN) and neuroendocrine 
carcinomas (NEC) or mixed neoplasms (MANEC);
 — histological G grading referring to well-differentiated 
neoplasms (NEN G1, NEN G2);
 — pTNM histopathological staging according to ENET 
and AJCC/UICC classification systems (it is important 
to provide affiliation of the classification in each case);
 — assessment of surgical margins.
Histopathological diagnosis of NEN must be necessarily 
confirmed by immunohistochemical tests assessing expres-
sion of the neuroendocrine markers: synaptophysin and 
chromogranin A, as well as the Ki-67 proliferative activity 
using the MIB1 antigen [62] (*evidence level 3).
3.3. Location diagnostics
3.3.1. Endoscopic diagnostics
The basic diagnostic method in colorectal NENs is co-
lonoscopy with biopsy for morphological assessment, 
supplemented by echoendoscopic examination (EUS). 
EUS is mainly performed in rectal lesions. In colonic 
tumours diagnosed as submucosal polyps/lesions, the 
colonoscopic assessment may be supplemented by 
mini-probe USG.
Colonic NENs are most frequently lesions which 
macroscopically resemble cancer infiltration; diagnosed 
early, they are in the form of submucosal polyps/tumours. 
Most rectal NENs (80%) demonstrate characteristic 
morphological features. They are nodules with a wide 
base, smooth at the surface, covered by a mucosa of nor-
mal appearance, or slightly yellow/white [5–9]. Atypical 
features (observed in 20%) include: semi-pedunculated 
shape, reddening of the mucosa, central depression, 
erosion or ulceration on the surface. Atypical features 
occur mostly in lesions larger than 1 cm. Ulceration of 
the surface is associated with a worse prognosis. Le-
sions are usually single. They are usually located in the 
middle part of the rectum. 
Contrary to other submucosal (subepithelial) le-
sions, in most patients (83%) with NEN, the biopsy 
results are positive [4]. This is due to the fact that NENs 
arise from the muscular layer of the mucosa. 
EUS allows the ability to distinguish an epithelial 
polyp from a NEN (different echogenicity of lesions 
and different layer from which the lesion derives), 
determines the stage of local advancement, and helps 
in choosing the optimal therapy (i.e. endoscopic or 
surgical treatment) [24, 25, 60]. Using EUS enables the 
ability to assess precisely the size of the lesion, deter-
mine the depth of infiltration, and describe the condi-
tion of lymph nodes. Sensitivity and specificity of this 
test in the assessment of the depth of infiltration is 87% 
and 93%, respectively [6]. Echoendoscopic features of 
colorectal NENs manifested as polyps include a well 
demarcated, iso- or hypoechogenic, homogenous le-
sion derived from the muscular layer of the mucosa. 
The lesion may infiltrate the submucosa; deeper layers 
are invaded less frequently.
In the case of neuroendocrine rectal lesions of up 
to 1 cm in diameter, some authors do not recommend 
EUS as a tool for assessment of the stage of disease 
advancement [26].
Classical colonoscopy is the basic examination in the 
diagnostics of colorectal tumours, including neuroen-
docrine lesions. Colorectal imaging is also possible with 
the use of video capsule endoscopy [27]. 
3.3.2. Other imaging examinations
As mentioned above, colonoscopy supplemented by EUS 
examination is of basic importance in the diagnostics of 
colorectal tumours. In the case of lesions closing the intes-
tinal lumen, full colonoscopy is impossible. In such cases, 
CT/MR colonography is recommended [20, 21].
To assess the stage of advancement, USG, CT/MR 
and SRS may be used. 
Abdominal ultrasound is a useful tool for the initial 
assessment of hepatic metastases and the possibility of 
fine-needle biopsy. Multiphase computed tomography 
or magnetic resonance is used to assess the lesions in 
the chest, abdominal cavity and pelvis. Scintigraphy 
of somatostatin receptors enables detection of lesions 
with increased SSTR expression, which is necessary to 
determine patient eligibility for the treatment with ‘hot’ 
somatostatin analogues.
In the case of negative SRS results, a PET/CT exami-
nation should be considered after the administration 
of 18 FDOPA, and for G2 and G3 NENs, PET/CT scan 
after the administration of 18 FDG [22, 23].
Minimal consensus on imaging:
 — Colonoscopy is the test of choice in the diagnostics of 
colorectal tumours;
 — CT/MR/SRS are recommended for the assessment of the 
stage of tumour advancement and detecting metastases 
(*evidence level 3–4).
* evidence level according to CEBM [65]
499
Endokrynologia Polska 2013; 64 (6)
4. Treatment
4.1. Surgical treatment
4.1.1. Surgical treatment of colonic NENs
In the surgical treatment of colonic NENs, it is recom-
mended to follow general rules adapted for colorectal 
adenocarcinomas. If possible (in surgical patients with 
the possibility of ensuring tumour-free proximal, distal 
and radial margins), it is recommended to perform 
a  radical resection appropriate for the part of the 
intestine, including the regional lymph nodes (*evi-
dence level 1). In NENs G1, G2 with distant metastases, 
mostly to the liver, a palliative resection with regional 
lymphadenectomy is recommended (*evidence level 1), 
or, if it is technically possible, maximal tumour cytore-
duction (*evidence level 2), even if complete reduction 
is not achieved [47]. In the case of invasion of the 
adjacent organs, if possible from the technical point of 
view, a multi-organ excision with left- or right-sided 
hemicolectomy is suggested, or extensive resections 
of the transverse colon, considering the extent of the 
lymphatic drainage (*evidence level 1) [48]. 
Figure 1 presents the recommended algorithm for 
the treatment of colonic neuroendocrine neoplasms 
(NENs).
4.1.2. Surgical treatment of rectal NENs
Patients with rectal NENs are referred to surgical therapy 
if the lesion does not qualify for endoscopic treatment 
(invasion of muscularis propria, regional lymph nodes 
metastases) (*evidence level 1). If there are no metastases to 
the regional lymph nodes, the tumour requires transrectal 
resection, as the risk of dissemination of the disease is 
lower than after anterior resection (*evidence level 1) [49, 
50]. In locally advanced tumours without distant metasta-
ses, resectional procedures are recommended, preferably 
saving the sphincters, as well as anterior resection with 
TME (total mesorectal excision), or, if necessary, abdomi-
nosacral amputation (*evidence level 1). Radical surgery is 
performed for tumours larger than 2 cm or between 1 and 
2 cm, if the muscular membrane is invaded. Surgery may 
be radical even in the case of lymph nodes invasion in 
T3 and T4 tumours, if no distant metastases are present 
[50–52]. The effect of radical resection on the development 
of distant metastases is not known. In locally and systemi-
cally advanced tumours with distant metastases, radical 
resection is not recommended (e.g. abdominosacral am-
putation of the rectum) due to an unfavourable prognosis. 
Survival is from six to a maximum of nine months after 
the diagnosis [53–56]. Only palliative anterior resection is 
accepted in the case of bleeding tumours, if local haemo-
stasis is unsuccessful (e.g. argon plasma coagulator, APC) 
or if obstruction occurs (*evidence level 1). In NENs G1, G2 
with metastases limited to the liver, a radical local excision 
of the tumour with subsequent resection of the hepatic 
parenchyma (metastasectomy) (*evidence level 1), or in 
certain cases, liver transplantation (*evidence level 4) may 
be considered [57, 58, 60]. In small tumours with perirectal 
lymph nodes metastases, aggressive surgical treatment is 
recommended, particularly in younger patients [50, 53]. 
Some of these patients may require palliative resection of 
the rectum due to obstruction or bleeding, or reduction 
of the tumour mass. In the case of other than hepatic 
distant metastases, aggressive surgical management does 
not significantly influence the length of survival. Figure 2 
presents the recommended algorithm for the treatment 
of rectal neuroendocrine neoplasms (NENs).
Figure 1. Algorithm for the treatment of colonic neuroendocrine 
neoplasms (NEN) (according to Caplin M et al. [12]). MR — 
nuclear magnetic resonance; CT — computed tomography; 
NEC — neuroendocrine carcinoma; G1, G2 — neuroendocrine 
neoplasms carcinoma; R1 — microscopically incomplete resection; 
R2 — macroscopically incomplete resection
Rycina 1. Algorytm leczenia nowotworów neuroendokrynnych 
(NEN) okrężnicy (wg Caplin M. i wsp. [12])
* evidence level according to CEBM [65]
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Minimal consensus on surgical treatment:
Minimal scope of surgical treatment refers to endoscopic 
excision (polypectomy) or transrectal local excision, resec-
tion with the extent depending on the tumour location (with 
the intention to treat/palliative), and possible cytoreductive 
procedure (*evidence level 1).
4.2. Endoscopic treatment of colorectal  
neuroendocrine neoplasms
Endoscopic treatment of colorectal NENs concerns 
mostly lesions in the rectum, because in colonic 
NENs surgical management is recommended due 
to the risk of regional lymph nodes metastases. The 
risk of lymph nodes metastases in colonic NENs is 
4% for lesions ≤ 1cm, limited to the mucosa, and 
over 14% for the remaining lesions [28]. 80% of rectal 
NENs are ≤ 1 cm; they invade the submucosa and 
give no metastases, so they can be qualified for local 
endoscopic treatment. Larger lesions, up to 2 cm, 
may also be treated endoscopically. It is conditional 
upon lack of infiltration of the muscularis propria, 
non-invaded lymph nodes, covering mucosa with-
out ulceration. 
Classical polypectomy cannot be performed in the 
treatment of colorectal neuroendocrine neoplasms, as 
these lesions derive from the second layer of the gastro-
intestinal wall and grow towards the submucosa. In most 
cases, with small lesions (up to 1 cm), endoscopic mucosal 
resection (EMR) is conducted, in different versions, as well 
as endoscopic mucosal dissection (ESD) [29–32]. The latter 
is considered the method of choice. ESD, compared to 
EMR, provides a higher ratio of en-bloc and R0 resections 
(100% v. 89% and 82–91% v. 65–70%).
The EMR method consists in submucosal adminis-
tration of certain substances, most often saline solution 
with adrenalin, and subsequent removal of the lesion 
with a diathermic loop. This method has a few variants. 
The most popular ones include: strip biopsy and cap 
assisted endoscopic mucosal resection (EMR-C). The 
strip biopsy technique requires using a two-channel 
Figure 2. Algorithm for the treatment of rectal neuroendocrine neoplasms (NENs) (modified according to Caplin M. et al. [12]). MR 
— nuclear magnetic resonance; CT — computed tomography; EUS — endoscopic ultrasonography; N(–) — non-invaded regional 
lymph nodes; N(+) — regional lymph nodes invaded with metastases; G1, G2 — neuroendocrine neoplasms; G3 — neuroendocrine 
carcinoma; TME — total mesorectal excision; T1 — infiltration does not transgress the submucosa; T2 — infiltration does not transgress 
the muscular membrane; T3 — infiltration does not transgress the serous membrane; T4 — infiltration penetrates the serosa; possible 
invasion of the adjacent organs
Rycina 2. Algorytm leczenia nowotworów neuroendokrynnych (NEN) odbytnicy (zmodyfikowano wg Caplin M. i wsp. [12])
* evidence level according to CEBM [65]
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endoscope. One channel is used to introduce forceps 
elevating the lesion after the initial injection, and the 
other to introduce the cutting loop. 
EMR-C is performed with the use of a classical endo-
scope. A plastic cap is placed at the end of the endoscope. 
After injecting the submucosa, the loop is placed on the 
edge of the cap, the lesion is aspirated into the cap, and 
then cut off with the loop. The basic limitation for the 
EMR techniques is the size of the lesion. Any neoplastic 
lesion that may be removed in one piece must be of 1–1.5 cm 
in diameter. Removing larger lesions is possible only via 
piecemeal resection, and is associated with a high risk of 
local recurrence (up to 5%).
ESD enables removing the tumour in one piece 
(en-bloc), within the healthy tissue, regardless of the 
size of the lesion, fibrosis or ulceration. Application of 
this method became possible after the Olympus Tokyo 
company had introduced a special knife (insulation tip-
IT knife) which reduces the risk of perforation due to 
a porcelain ball-shaped tip. The procedure starts with 
marking the borders of the lesion, allowing for a healthy 
tissue margin. Saline solution with diluted adrenalin 
and indigo carmine is injected into the submucosa in 
order to elevate it and increase its volume. When a small 
incision is made, the next steps include performing a 
round incision and dissection of the lesion within the 
submucosa. Endoscopic treatment is associated with 
very good distant results [30].
ESD procedures are performed in Poland in the 
following centres: General, Gastroenterological and 
Gastrointestinal Neoplasms Surgical Teaching Hospital, 
Medical University of Lublin; Endotherapy Non-public 
Health Care Facility in Warsaw, and the Department 
of Gastroenterology, Pomeranian Medical University 
in Szczecin. Szczecin has seen the largest number of 
procedures performed [15].
Minimal consensus on endoscopic treatment:
Endoscopic treatment of colorectal NENs concerns mostly 
lesions in the rectum.
With lesions of up to 1 cm — endoscopic mucosal resection 
and endoscopic submucosal dissection (*evidence level 3).
4.3. Medical treatment
4.3.1. Biotherapy
Somatostatin analogues (SSA), m-TOR inhibitors:
Carcinoid syndrome is extremely rare in colo-
rectal neuroendocrine neoplasms. If it is present, 
the primary tumour probably arises from the initial 
section of the large intestine. In the case of dis-
seminated neoplastic process with the symptoms of 
excessive serotonin secretion, using SSA is the treat-
ment of choice (evidence level 1). In non-functional 
neuroendocrine neoplasms (NF-NENs), there is no 
conclusive evidence of anti-neoplastic effectiveness 
of somatostatin analogues [12], but their effectiveness 
may not be excluded, due to the recently published 
results of the CLARINET, RADIANT-2 study and Pol-
ish observations [33, 59, 64].
A detailed analysis of the RADIANT-2 subgroups, 
including only the patients with advanced G1/G2 colo-
rectal NENs (39 cases, mostly with primary tumours 
located in the colon) has demonstrated that, statisti-
cally, the progression-free survival of the patients who 
received everolimus plus octreotide LAR (19 patients, 
including 14 with histological grade G1) was signifi-
cantly longer (median PFS 29.9 months) than in the 
patients receiving placebo plus octreotide LAR (20 
patients, including 12 with the histological grade G1) 
(median PFS 6.6 months; the hazard ratio was HR: 0.34; 
95% CI:0.13-0.89; p = 0.011, which resulted in a 66% 
relative reduction in the risk of progression in patients 
treated with everolimus. Tumour regression (not meet-
ing the CR and PR RECIST criteria) was observed in the 
everolimus arm in 67% of patients, and in the placebo 
arm in 37%. Assessment of the role of somatostatin 
analogues in the treatment of colorectal G1/G2 NENs 
is difficult due to the lack of a referential arm, in which 
only placebo would be administered; however, everoli-
mus seems to be active in these cases (*evidence level 3). 
4.3.2. Systemic chemotherapy
Systemic chemotherapy is primarily dedicated to 
neuroendocrine carcinomas (NECs). Detailed recom-
mendations are presented in the section on general 
recommendations in GEP NENs (see pp. 418–443).
In the case of progression of advanced non-small cell 
NEC, after the treatment with cisplatin and etoposide, 
a second-line chemotherapy may be considered, includ-
ing temozolomide + bevacizumab (± kapecitabin) or 
irinotecan plus 5-FU [34, 35] (*evidence level 4). 
If we can immunohistochemically determine the ex-
pression of O6-methylguanine-DNA-methyl transferase 
(MGMT), which is a DNA repair enzyme responsible for 
the removal of methyl groups from guanine in the O6 
position, then in the absence of staining the neoplastic 
cells for MGMT, a temizolomide-based chemotherapy 
regimen may be introduced in the treatment of colo-
rectal NEN (*evidence level 4).
Patients with MANEC of the large intestine should be 
treated following the standards of the oncological man-
agement dedicated to classical colorectal carcinomas [34].
* evidence level according to CEBM [65]
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Minimal consensus statement on medical therapy:
Advanced non-functional G1/G2 NEN — somatostatin 
analogues with or without everolimus may be considered; 
in the case of progression, systemic chemotherapy based on 
5-fluorouracil (e.g. 5-FU + doxorubicin + streptozocin).
The basic treatment of NEC is chemotherapy based on 
platinum derivatives (*evidence level 3).
4.4. Radioisotope treatment
There is no separate data concerning the effectiveness 
of targeted therapy with radioisotope labelled somato-
statin analogues (PRRT) in the group of patients with 
colorectal NENs. Eligibility for the treatment is in ac-
cordance with the principles described in the general 
section.
Taking into account the high degree of effectiveness 
of PRRT in other GEP NENs, PRRT should be consid-
ered in patients with disseminated or non-surgical 
NENs G1, G2, with increased somatostatin receptor 
expression confirmed in the scintigraphic examination, 
if other available treatment methods prove ineffective 
[36–46].
Minimal consensus statement on isotope treatment:
PRRT should be considered in patients with disseminated 
or non-surgical G1 and G2 NENs, with increased somatosta-
tin receptor expression demonstrated in SRS, if other available 
treatment methods prove ineffective (*evidence level 4).
4.5. Follow-up
After a complete endoscopic or surgical removal of the 
colorectal neuroendocrine neoplasm, the following 
follow-up is recommended [12]:
 — G1, G2 tumours up to 1 cm, without the lymph 
nodes metastases, without invasion of the muscu-
laris propria: regular monitoring of patients is not 
recommended; 
 — G3 tumours smaller than 1 cm and G1–3 tumours 
of 1–2 cm: colonoscopy every year;
 — tumours larger than 2 cm: obligatory follow-up 
examinations;
 — G1/G2: colonoscopy/imaging examination/CgA in 
the first year; for G3 tumours, the same examinations 
every 4–6 months in the first year, then once a year.
Follow-up imaging examinations:
 — For lesions in the rectum: EUS, colonoscopy, MR
 — For lesions in the colon: CT, colonoscopy
 — Liver assessment: contrast-enhanced MR, multi-
detector CT
 — It is recommended to determine serum CgA for 
ten years. 
A precise system of risk assessment for rectal NENs 
has been developed, including a combination of four 
features: size, depth of invasion, vascular invasion, 
and mitotic index [6]. Each parameter can be awarded 
0–2 points (Table IV). Zero points means a low-risk 
patient, 1–2 points – a patient of medium risk, and 3 or 
more points — a high-risk patient. Low-risk patients 
(lesion < 1 cm, limited to the mucosa/submucosa, 
without vascular invasion, mitotic index < 2/50 HPF) 
do not require imaging tests for the assessment of the 
stage of the disease, and do not need monitoring. In 
medium-risk patients, imaging examinations should 
be considered and follow-up tests performed. High-
risk patients require imaging examinations before the 
planned treatment, and frequent follow-up examina-
tions, due to a high risk of distant metastases (47%) and 
local recurrence (31%).
Risk assessment: 0 points — low risk, 1–2 points — 
medium risk, ≥ 3 points — high risk.
Minimal consensus statement on follow-up:
 — For lesions in the rectum: EUS, colonoscopy, MR
 — For lesions in the colon: CT, colonoscopy
 — Liver assessment: contrast-enhanced MR, multidetector CT
 — All lesions larger than 2 cm will require follow-up; smaller 
tumours should be followed up in the presence of poor 
prognostic factors (*evidence level 3).
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